Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Diabetes Mellitus, Type 2 2Rectal Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Diabetes Mellitus 1

Interventions

relacorilant 5Pioglitazone 4Metformin 4Sitagliptin Phosphate 3Resistance Training 3Dipeptidyl-Peptidase IV Inhibitors 3saxagliptin 2Vildagliptin 2Sulfonylurea Compounds 2Rosiglitazone 2Nutritional Status 2Blood Specimen Collection 2voglibose 1somapacitan 1semaglutide 1repaglinide 1pembrolizumab 1miglitol 1metahexamide 1meglitinide 1mazdutide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1empagliflozin 1dapagliflozin 1alogliptin 1Urine Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Diabetes Mellitus, Type 2 × saxagliptin × Clear all
NCT07033585 2025-07-11

GD-T2D

Medicine Invention Design, Inc

Phase 2/3 Active not recruiting
600 enrolled

Diabetes Mellitus, Diabetes Mellitus, Type 2

NCT02475499 2016-03-14

Incretin-based Drugs and Pancreatic Cancer

Canadian Network for Observational Drug Effect Studies, CNODES

Completed
886,172 enrolled
Gastrointestinal

Diabetes Mellitus, Type 2, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡